Items Tagged ‘Alecensa’

June 12th, 2017

Alecensa Superior to Xalkori in Treatment of Lung Cancer

By

Alecensa (alectinib) halted the spread of lung cancer for a median of 15 months longer than treatment with rival Xalkori (crizotinib) with fewer side effects, according to trial results presented at the 2017 American Society of Clinical Oncology annual meeting in Chicago. Both drugs are designed to treat advanced non-small cell lung cancer (NSCLC) in […]

View full entry

Tags: Alecensa, alectinib, ALK gene, ALK-positive NSCLC, crizotinib, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, precision medicine, xalkori


December 24th, 2015

Alecensa ™ Approved for the Treatment of Recurrent ALK-Positive Lung Cancer

By

The FDA approved another inhibitor of anaplastic lymphoma kinase (ALK) for treatment of non-small cell lung cancer (NSCLC) today, further expanding precision treatment options. Alecensa ™ (Alectinib) is indicated for advanced, metastatic, ALK-positive NSCLC in patients unresponsive to or intolerant of another ALK inhibitor, Xalkori ™ (crizotinib). The investigative agent, Alecensa, produces high anti-cancer responses […]

View full entry

Tags: Alecensa, alectinib, alk-positive, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc